A large number of laboratory investigations reported on inhibitory effects of selective COX-2 inhibitors on various stages of glioma pathogenesis [3–6, 8–13, 15, 18–23], prompting clinical trials to investigate selective COX-2 inhibitors as adjuvant therapy for glioma [24–32]. This evidence concerns the gene PTGS2 and glioma.